Apogee Therapeutics (APGE) Total Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Non-Current Liabilities data on file, last reported at $37.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $37.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.3 million (changed N/A YoY) and the FY2025 annual result came in at $31.2 million, down 15.94% from the prior year.
• Total Non-Current Liabilities rose to $37.3 million in Q1 2026 per APGE's latest filing, from $31.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $41.4 million in Q3 2024 and bottomed at $2.0 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $28.5 million (2024), against an average of $25.9 million.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities jumped 722.78%; it then decreased 15.94% in 2025.
• Tracing APGE's Total Non-Current Liabilities over 5 years: stood at $2.0 million in 2022, then jumped by 722.78% to $16.3 million in 2023, then jumped by 127.47% to $37.1 million in 2024, then declined by 15.94% to $31.2 million in 2025, then gained by 19.61% to $37.3 million in 2026.
• Per Business Quant, the three latest APGE Total Non-Current Liabilities figures stand at $37.3 million (Q1 2026), $31.2 million (Q4 2025), and $39.8 million (Q3 2025).

Peer Comparison